BeOne Medicines(BEIGF)
CA - San CarlosBiotechnology
Focus: BeOne Medicines is a 12,000-person public biotech company headquartered in San Carlos, CA, generating $2.5B in FY2025 revenue primarily from its flagship BTK inhibitor BRUKINSA (zanubrutinib). They operate across oncology, nephrology, immunology, and dermatology with a diversified pipeline of small molecules and monoclonal antibodies.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Employees
12,000
Open Jobs
276+60 this month
Hot — 171 jobs added in 30d
Net +60 (171 new, 111 removed). Aggressive expansion phase.
Should You Work at BeOne Medicines?
AI assessmentAttractive for commercial and medical affairs professionals riding a successful launch cycle, but oncology scientists should stress-test pipeline probability of success given the company's financial dependency on one asset.
Why Work Here
- Strong revenue growth (78% YoY: $1.4B to $2.5B) with $3.2B cash on hand demonstrates financial runway and scaling momentum.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$2.5B
Key Products
$801M Part DGrowing
Launch16.6yr
Flagship BTK inhibitor driving 100% of company revenue; long patent runway (2043 LOE) provides decade-plus exclusivity window.
Help build intelligence for BeOne Medicines
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.